CN114053331B - 一种口腔抑菌组合物、口腔抑菌液、应用及制备方法 - Google Patents
一种口腔抑菌组合物、口腔抑菌液、应用及制备方法 Download PDFInfo
- Publication number
- CN114053331B CN114053331B CN202010750056.4A CN202010750056A CN114053331B CN 114053331 B CN114053331 B CN 114053331B CN 202010750056 A CN202010750056 A CN 202010750056A CN 114053331 B CN114053331 B CN 114053331B
- Authority
- CN
- China
- Prior art keywords
- extract
- oral
- preparation
- parts
- honeysuckle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 239000007788 liquid Substances 0.000 title claims abstract description 46
- 239000000284 extract Substances 0.000 claims abstract description 141
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 48
- 239000010231 banlangen Substances 0.000 claims abstract description 30
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 241000576429 Forsythia suspensa Species 0.000 claims abstract description 15
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims abstract description 13
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims abstract description 13
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims abstract description 12
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims abstract description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 81
- 238000001914 filtration Methods 0.000 claims description 33
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 28
- 229940069445 licorice extract Drugs 0.000 claims description 26
- 241000334160 Isatis Species 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 17
- 230000003385 bacteriostatic effect Effects 0.000 claims description 16
- 238000002137 ultrasound extraction Methods 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 10
- 241000202807 Glycyrrhiza Species 0.000 claims description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 229940010454 licorice Drugs 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 108010059892 Cellulase Proteins 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940106157 cellulase Drugs 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000686 essence Substances 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 abstract description 9
- 208000002399 aphthous stomatitis Diseases 0.000 abstract description 9
- 230000035876 healing Effects 0.000 abstract description 9
- 231100000397 ulcer Toxicity 0.000 abstract description 9
- 230000007794 irritation Effects 0.000 abstract description 6
- 208000007117 Oral Ulcer Diseases 0.000 abstract description 5
- 239000000668 oral spray Substances 0.000 abstract description 5
- 229940041678 oral spray Drugs 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 54
- 230000002829 reductive effect Effects 0.000 description 20
- 210000000214 mouth Anatomy 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000012467 final product Substances 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 206010006326 Breath odour Diseases 0.000 description 6
- 241000628997 Flos Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 206010015946 Eye irritation Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 231100000013 eye irritation Toxicity 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000032139 Halitosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000006916 nutrient agar Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013588 oral product Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- -1 sterol compound Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- XUDNWQSXPROHLK-OACYRQNASA-N 2-phenyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC=CC=2)OC2=CC=CC=C2C1=O XUDNWQSXPROHLK-OACYRQNASA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930002339 quinazoline alkaloid Natural products 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及口腔抑菌技术领域,尤其涉及一种口腔抑菌组合物及其应用和该口腔抑菌组合物制成的口腔抑菌液及其制备方法。该口腔抑菌组合物包括以下重量份数的成分:连翘提取液0.05~0.3份,金银花提取液0.05~0.3份,甘草提取液0.05~0.3份,板蓝根提取液0.05~0.3份,西吡氯铵0.02~0.1份和葡萄糖酸氯己定0.02~0.1份。该口腔抑菌组合物具有快速且长效的抑菌作用,能够有效清新口气,并且对于口腔溃疡的溃疡面无刺激,还能够加速口腔溃疡愈合。用该口腔抑菌组合物可制成口腔喷雾等口腔抑菌产品。
Description
技术领域
本发明涉及口腔抑菌技术领域,尤其涉及一种口腔抑菌组合物及其应用和该口腔抑菌组合物制成的口腔抑菌液及其制备方法。
背景技术
口腔作为呼吸道及胃肠道的起点,是机体内环境与外环境直接联系的门户,外环境生态系统中许多细菌可通过呼吸、进食等各种日常生命活动不断进入口腔,并在温暖湿润的口腔中繁殖。链球菌、葡萄球菌和乳酸杆菌等会引发各种口腔疾病,如龋齿、口臭、牙龈炎等。由于口腔内缝隙多且细小,日常刷牙难以对致病菌进行彻底清理,故龋齿和牙龈炎还会进一步加重口臭。另一方面,随着现代人生活节奏加快、工作压力增大,不健康的作息(如熬夜)以及饮食习惯(如不定时进餐,喜食麻、辣、烫等重口味食物)会导致身体内分泌异常,进而引起口腔内酸碱平衡度失调、口腔溃疡,以及牙龈肿痛、出血、萎缩等口腔问题,同样可导致口臭。
由于口臭严重干扰着人们社交和心理健康,所以口臭者多采用含片、袋泡茶、口香糖等进行遮蔽,但是这些方法耗时费力,且仅能短暂起效,并不能从根本上解决口臭问题。含有抗生素成分的口腔喷雾可杀灭或抑制口腔内细菌,但大多具有一定的刺激性,当口腔内有溃疡时,会造成使用者明显刺痛,并且长期使用含抗生素成分的口腔喷雾还可能使口腔内菌群失调,并诱导口腔细菌产生耐药性。
发明内容
针对目前的口腔喷雾具有一定刺激性、可引起口腔内菌群失调并使细菌产生耐药性的问题,本发明提供一种口腔抑菌组合物、口腔抑菌液、应用及制备方法。
为达到上述发明目的,本发明实施例采用了如下技术方案:
一方面,本发明实施例提供一种口腔抑菌组合物,包括以下重量份数的成分:连翘提取液0.05~0.3份,金银花提取液0.05~0.3份,甘草提取液0.05~0.3份,板蓝根提取液0.05~0.3份,西吡氯铵0.02~0.1份和葡萄糖酸氯己定0.02~0.1份。
在该口腔抑菌组合物中,西吡氯铵通过降低表面张力而抑制和杀灭细菌,对多种口腔致病菌和非致病菌有抑制和杀灭作用,并能减少或抑制牙菌斑的形成,具有保持口腔清洁、清除口腔异味的作用。葡萄糖酸氯己定能够吸附于细菌胞浆膜的渗透屏障,使细胞内容物漏出而发挥抗菌作用,抗菌谱广,杀菌作用强。
连翘果实含连翘酚、甾醇化合物、三萜皂甙及黄酮醇甙类、马苔树脂醇甙等成分,果皮含齐墩果酸、香豆精等成分,其提取液对口腔常见的致病菌具有一定的抑制作用,并可抑制流感病毒;金银花含有木犀草素、肌醇、皂甙、绿原酸和异绿原酸等成分,其提取液对多种口腔致病菌以及病毒均有一定的抑制和杀灭作用。
甘草含有三萜皂苷和黄酮类化合物等活性成分,其提取液具有抗炎、抗菌、抗病毒、镇咳、抗溃疡、祛痰、抗氧化、抗癌、免疫调节等多种药理活性,能够抑制人类免疫缺陷病毒(HIV-1)、传染性非典型肺炎病毒(SARS)、呼吸系统病毒、水泡性口膜炎病毒等多种病毒的增殖。
板蓝根含有吲哚类化合物、喹唑类生物碱、芥子苷类化合物、含硫类化合物、有机酸类等成分,其提取液具有清热解毒、凉血利咽的作用,可抑制多种口腔常见致病菌,并对甲型流感病毒、乙型脑炎病毒、腮腺炎病毒、流感病毒的增殖有抑制作用。
本发明通过以上成分复配,所得口腔抑菌组合物具有快速且长效的抑菌作用,能够有效清新口气。并且,本发明经过研究发现,将连翘提取液、金银花提取液、甘草提取液和板蓝根提取液合用,能够使该组合物不仅对于口腔溃疡的溃疡面无刺激,还具有加速口腔溃疡愈合的作用。
优选地,所述口腔抑菌组合物包括以下重量份数的成分:连翘提取液0.1~0.2份,金银花提取液0.1~0.2份,甘草提取液0.1~0.2份,板蓝根提取液0.1~0.2份,西吡氯铵0.08~0.1份和葡萄糖酸氯己定0.06~0.08份。
优选地,所述口腔抑菌组合物包括以下重量份数的成分:连翘提取液0.1份,金银花提取液0.1份,甘草提取液0.1份,板蓝根提取液0.1份,西吡氯铵0.08份和葡萄糖酸氯己定0.06份。以上成分采用该配比时具有更持久的抑菌作用,且能更有效地加速口腔溃疡愈合。
可选地,所述甘草提取液的制备方法为:将生甘草粉碎,加入相当于所述生甘草质量5~7倍的水煎煮1~1.5h,降温至40~50℃后,加入相当于所述生甘草质量0.5~1.5%的纤维素酶在40~50℃酶解2~3h,然后升温至90~95℃保持5~10min灭酶,过滤,得酶解液和滤渣;向所述滤渣中加入相当于所述滤渣质量5~7倍的水,在20~30kHz的频率下超声提取20~30min,过滤,得超声提取液;将所述酶解液和所述超声提取液合并后,浓缩至1.2~1.3g/ml,得所述甘草提取液。
可选地,所述板蓝根提取液的制备方法为:将板蓝根破碎,加入相当于所述板蓝根质量6~8倍的10~20%v/v乙醇水溶液,在功率为750~950W、温度为30~40℃条件下微波萃取10~15min,过滤,得滤渣和微波提取液;将所述滤渣用15~25%v/v乙醇水溶液回流提取2~3次,每次20~30min,合并回流提取液;将所述微波提取液和所述回流提取液合并,浓缩至1.2~1.3g/ml,得所述板蓝根提取液。
用上述制备方法制得的甘草提取液和板蓝根提取液均能够使该口腔抑菌组合物具有更好的长效抑菌效果,并且能更显著地加速口腔溃疡愈合。
可选地,所述连翘提取液的制备方法为:以15~25%v/v乙醇水溶液在25~35℃对连翘进行超声提取,先在25~35kHz的频率下提取20~30min,再在50~70kHz的频率下提取15~25min;提取完成后过滤,将所得滤液浓缩至1.2~1.3g/ml,得所述连翘提取液;其中,所述15~25%v/v乙醇水溶液的质量为所述连翘质量的5~8倍。
可选地,所述金银花提取液的制备方法为:以45~65%v/v乙醇水溶液在45~60℃对金银花进行超声提取,先在20~35kHz的频率下超声提取20~30min,再在55~70kHz的频率下超声提取15~20min;提取完成后过滤,将所得滤液浓缩至1.2~1.3g/ml,得所述金银花提取液;其中,所述45~65%v/v乙醇水溶液的质量为所述金银花质量的7~10倍。
用上述制备方法获得的连翘提取液和金银花提取液均能够进一步提高该口腔抑菌组合物的抑菌效果,并延长抑菌时间,且能够降低该组合物对黏膜以及溃疡面的刺激性。
第二方面,本发明实施例还提供了上述口腔抑菌组合物在制备口腔抑菌产品中的应用。
上述口腔抑菌组合物对于口腔常见致病菌具有快速而长效的抑菌效果,对皮肤和口腔黏膜温和、安全,并且对于口腔溃疡等口腔问题具有显著的改善作用,可用于制备口腔抑菌产品。
第三方面,本发明实施例还提供了一种口腔抑菌液,包括上述口腔抑菌组合物。该口腔抑菌液可作为漱口水用于含漱,也可灌装于喷雾装置中作为口腔喷雾剂,使用简单,并且携带方便。
所述口腔抑菌液包括以下重量份数的成分:
所述保湿剂为甘油;
所述矫味剂选自木糖醇、三氯蔗糖中的至少一种,其中木糖醇是一种天然、健康的甜味剂,在增加该口腔抑菌液甜味的同时,还能够带来一定的清凉感,并有助于增强牙齿的清洁度,减少牙斑菌的附着;
所述抗氧剂为柠檬酸钠。
以上优选的原料均为口腔用产品的常用组分,安全性高,对口腔黏膜无刺激,在上述用量范围内使用不会引起口腔不适。
第四方面,本发明还提供上述口腔抑菌液的制备方法,包括以下步骤:
向所述水中加入所述保湿剂、矫味剂、西吡氯铵、葡萄糖酸氯己定和抗氧剂,搅拌至溶解;
加入所述连翘提取液、金银花提取液、甘草提取液和板蓝根提取液,搅拌分散均匀;
加入预混均匀的所述乙醇、聚山梨醇酯-80和香精,混合均匀,得所述口腔抑菌液。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合具体实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用于解释本发明,并不用于限定本发明。
以下实施例中所采用的实验方法如无特殊说明,均为本领域的常规方法。
以下实施例中所使用的连翘、金银花、生甘草和板蓝根均符合《中国药典》(2015年版)一部正文各药材项下的有关规定。
以下实施例中所采用的原料、试剂等,如无特殊说明,均从商业途径获得。
实施例1~9
本发明口腔抑菌组合物的制备:各实施例中包括以下如表1所示的重量份数配比的成分:
表1实施例1~9口腔抑菌组合物
实施例1中,连翘提取液的制备方法为:以20%v/v乙醇水溶液在30℃超声提取:先在30kHz提取25min,再在60kHz的频率下提取20min;提取完成后过滤,将所得滤液在50℃减压浓缩至1.25g/ml,即得;其中,20%v/v乙醇水溶液的质量为连翘质量的6倍;
金银花提取液的制备方法为以55%v/v乙醇水溶液在50℃超声提取:先在30kHz超声提取25min,再在60kHz的频率下超声提取18min;提取完成后过滤,将所得滤液在50℃减压浓缩至1.25g/ml,即得;其中,55%v/v乙醇水溶液的质量为金银花质量的8倍;
甘草提取液的制备方法为:将生甘草粉碎,加入相当于其质量6倍的水煎煮1.2h,降温至45℃后,加入相当于该生甘草质量1.0%的纤维素酶在45℃酶解2.5h,然后升温至93℃保持8min灭酶,过滤,得酶解液和滤渣;向该滤渣中加入相当于其质量6倍的水,在25kHz的频率下超声提取25min,过滤,得超声提取液;将酶解液和超声提取液合并后,在50℃减压浓缩至1.25g/ml,即得;
板蓝根提取液的制备方法为:将板蓝根破碎,加入相当于其质量7倍的15%v/v乙醇水溶液,在功率为850W、温度为35℃条件下微波萃取12min,过滤,得滤渣和微波提取液;将滤渣用20%v/v乙醇水溶液回流提取2次,每次25min,合并回流提取液;将微波提取液和回流提取液合并,在50℃减压浓缩至1.25g/ml,即得。
实施例2中,连翘提取液的制备方法为以15%v/v乙醇水溶液在25℃超声提取:先在25kHz提取30min,再在50kHz的频率下提取25min;提取完成后过滤,将所得滤液在50℃减压浓缩至1.2g/ml,即得;其中,15%v/v乙醇水溶液的质量为连翘质量的5倍;
金银花提取液的制备方法为以45%v/v乙醇水溶液在45℃超声提取:先在20kHz超声提取30min,再在55kHz的频率下超声提取20min;提取完成后过滤,将所得滤液在50℃减压浓缩至1.2g/ml,即得;其中,45%v/v乙醇水溶液的质量为金银花质量的7倍;
甘草提取液的制备方法为:将生甘草粉碎,加入相当于其质量5倍的水煎煮1h,降温至50℃后,加入相当于该生甘草质量0.5%的纤维素酶在50℃酶解2h,然后升温至95℃保持5min灭酶,过滤,得酶解液和滤渣;向该滤渣中加入相当于其质量5倍的水,在20kHz的频率下超声提取30min,过滤,得超声提取液;将酶解液和超声提取液合并后,在50℃减压浓缩至1.2g/ml,即得;
板蓝根提取液的制备方法为:将板蓝根破碎,加入相当于其质量6倍的20%v/v乙醇水溶液,在功率为750W、温度为40℃条件下微波萃取10min,过滤,得滤渣和微波提取液;将滤渣用15%v/v乙醇水溶液回流提取3次,每次30min,合并回流提取液;将微波提取液和回流提取液合并,在50℃减压浓缩至1.2g/ml,即得。
实施例3中,连翘提取液的制备方法为以25%v/v乙醇水溶液在35℃超声提取:先在35kHz提取20min,再在70kHz的频率下提取15min;提取完成后过滤,将所得滤液在50℃减压浓缩至1.3g/ml,即得;其中,25%v/v乙醇水溶液的质量为连翘质量的8倍;
金银花提取液的制备方法为以65%v/v乙醇水溶液在60℃超声提取:先在35kHz超声提取20min,再在70kHz的频率下超声提取15min;提取完成后过滤,将所得滤液在50℃减压浓缩至1.25g/ml,即得;其中,65%v/v乙醇水溶液的质量为金银花质量的10倍;
甘草提取液的制备方法为:将生甘草粉碎,加入相当于其质量7倍的水煎煮1.5h,降温至40℃后,加入相当于该生甘草质量1.5%的纤维素酶在40℃酶解3h,然后升温至90℃保持10min灭酶,过滤,得酶解液和滤渣;向该滤渣中加入相当于其质量7倍的水,在30kHz的频率下超声提取20min,过滤,得超声提取液;将酶解液和超声提取液合并后,在50℃减压浓缩至1.3g/ml,即得;
板蓝根提取液的制备方法为:将板蓝根破碎,加入相当于其质量8倍的10%v/v乙醇水溶液,在功率为950W、温度为30℃条件下微波萃取15min,过滤,得滤渣和微波提取液;将滤渣用25%v/v乙醇水溶液回流提取2次,每次20min,合并回流提取液;将微波提取液和回流提取液合并,在50℃减压浓缩至1.3g/ml,即得。
实施例4~9中,连翘提取液、金银花提取液、甘草提取液和板蓝根提取液的制备方法同实施例1。
实施例10~18
本发明提供了口腔抑菌液及其制备方法:各实施例中包括以下如表2所示的重量份数配比的成分:
表2实施例10~18口腔抑菌液
其中连翘提取液、金银花提取液、甘草提取液和板蓝根提取液的制备方法同实施例1。
该口腔抑菌液的制备方法为:
向水中加入甘油、木糖醇、三氯蔗糖、葡萄糖酸氯己定和柠檬酸钠,搅拌至溶解;
加入连翘提取液、金银花提取液、甘草提取液和板蓝根提取液,搅拌分散均匀;
加入预混均匀的乙醇、聚山梨醇酯-80和香精,混合均匀,即得口腔抑菌液。
对比例1
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中甘草提取液的制备方法为:将生甘草粉碎,用相当于其质量6倍的水煎煮提取2次,每次30min;过滤,合并滤液,将滤液在50℃减压浓缩至1.25g/ml,即得;
连翘提取液、金银花提取液和板蓝根提取液制备方法同实施例1。
对比例2
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中甘草提取液的制备方法为:将生甘草粉碎,用相当于其质量6倍的水溶液超声提取45min,超声频率为25Hz;过滤,将滤液在50℃减压浓缩至1.25g/ml,即得;
连翘提取液、金银花提取液和板蓝根提取液的制备方法同实施例1。
对比例3
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中板蓝根提取液的制备方法为:将板蓝根破碎,用相当于其质量7倍的20%v/v乙醇水溶液加热回流提取2次,每次25min;过滤,合并滤液,将滤液在50℃减压浓缩至1.25g/ml,即得;
连翘提取液、金银花提取液和甘草提取液的制备方法同实施例1。
对比例4
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中板蓝根提取液的制备方法为:将板蓝根破碎,用相当于其质量7倍的15%v/v乙醇水溶液在功率为850W、温度为35℃条件下微波萃取12min,过滤,将滤液在50℃减压浓缩至1.25g/ml,即得;
连翘提取液、金银花提取液和甘草提取液的制备方法同实施例1。
对比例5
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中连翘提取液的制备方法为:将连翘用6倍的20%v/v乙醇水溶液加热回流提取2次,每次30min;过滤,合并滤液,将滤液在50℃减压浓缩至1.25g/ml,即得;
金银花提取液、甘草提取液和板蓝根提取液的制备方法同实施例1。
对比例6
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中连翘提取液的制备方法为:将连翘用6倍的20%v/v乙醇水溶液超声提取45min,超声频率为45Hz;过滤,将滤液在50℃减压浓缩至1.25g/ml,即得;
金银花提取液、甘草提取液和板蓝根提取液的制备方法同实施例1。
对比例7
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中金银花提取液的制备方法为:将金银花用8倍的55%v/v乙醇水溶液加热回流提取2次,每次30min;过滤,将滤液在50℃减压浓缩至1.25g/ml,即得;
连翘提取液、甘草提取液和板蓝根提取液的制备方法同实施例1。
对比例8
本对比例提供一种口腔抑菌组合物,其成分同实施例1。
其中金银花提取液的制备方法为:将金银花用8倍的55%v/v乙醇水溶液超声提取45min,超声频率为45Hz;过滤,将滤液在50℃减压浓缩至1.25g/ml,即得;
连翘提取液、甘草提取液和板蓝根提取液的制备方法同实施例1。
对比例9
本对比例提供一种口腔抑菌组合物,包括以下重量份数配比的成分:
西吡氯铵0.08份和葡萄糖酸氯己定0.06份。
对比例10
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中连翘提取液、金银花提取液和板蓝根提取液的制备方法同实施例1,甘草提取液的制备方法同对比例1。
对比例11
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中连翘提取液、金银花提取液和板蓝根提取液的制备方法同实施例1,甘草提取液的制备方法同对比例2。
对比例12
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中连翘提取液、金银花提取液和甘草提取液的制备方法同实施例1,板蓝根提取液的制备方法同对比例3。
对比例13
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中金银花提取液、柑橘提取液和甘草提取液的制备方法同实施例1,板蓝根提取液的制备方法同对比例4。
对比例14
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中金银花提取液、甘草提取液和板蓝根提取液的制备方法同实施例1,连翘提取液的制备方法同对比例5。
对比例15
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中金银花提取液、甘草提取液和板蓝根提取液的制备方法同实施例1,连翘提取液的制备方法同对比例6。
对比例16
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中连翘提取液、甘草提取液和板蓝根提取液的制备方法同实施例1,金银花提取液的制备方法同对比例7。
对比例17
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比和制备方法同实施例10,其中连翘提取液、甘草提取液和板蓝根提取液的制备方法同实施例1,金银花提取液的制备方法同对比例8。
对比例18
本对比例提供一种口腔抑菌液及其制备方法,该口腔抑菌液的成分配比以实施例10为基础,去掉连翘提取液、金银花提取液、甘草提取液和板蓝根提取液,其余成分不变,制备方法同实施例10。
试验例1
本试验例对上述实施例1~9和对比例1~9制备所得口腔抑菌组合物进行了抑菌效果考察。
下述实验中所采用的营养琼脂培养基的成分配比为:蛋白胨10g,牛肉膏3g,氯化钠5g,琼脂17g,蒸馏水1000mL;
沙氏培养基的成分为:蛋白胨10g、琼脂20g、葡萄糖40g,蒸馏水1L。
试验菌株:金黄色葡萄球菌(ATCC6538)、大肠杆菌(8099)、白色念珠菌(ATCC10231)。
1、实验方法
将试验菌第5代的营养琼脂培养基斜面培养物(24h)用5mL 0.03mol/L磷酸盐缓冲液(以下简称PBS)洗下菌苔,用上述PBS稀释,制成浓度为5×104cfu/ml的菌悬液。
以实施例1~9和对比例1~9制备所得口腔抑菌组合物样品作为被试样液,取被试样液(5mL)和对照样液(与被试样液成分相同,但不含连翘提取液、金银花提取液、甘草提取液、板蓝根提取液、西吡氯铵和葡萄糖氯己定,且经灭菌处理)各4管。
分别在每个被试样液和对照样液内滴加100μL上述菌悬液,均匀混合,开始计时,作用2min、5min、10min、20min、1h、2h,用无菌镊分别将混合后的样液(0.5mL)投入含5mLPBS的试管内,充分混匀,分别吸取0.5ml,置于两个平皿,用凉至40~50℃的营养琼脂培养基(细菌)或沙氏琼脂培养基(酵母菌)15mL作倾注,转动平皿,使其充分均匀,琼脂凝固后翻转平板,35℃±2℃培养48h(细菌)或72h(酵母菌),作活菌菌落计数。
试验重复3次,按下式计算抑菌率:
X=(A-B)/A×100%;
式中:X为抑菌率,A为对照样液平均菌落数;B为被试样液平均菌落数。
2、实验结果
记录各口腔抑菌组合物在不同作用时间下的抑菌率平均值,结果见表3~5。
表3对金黄色葡萄球菌的抑菌数据
表4对大肠杆菌的抑菌数据
表5对白色念珠菌的抑菌数据
由表3~表5试验结果可见,本发明实施例1~9所得口腔抑菌组合物对金黄色葡萄球菌和大肠杆菌的抑菌率在5min~2h时均>99.9%,优于各对比例对金黄色葡萄球菌和大肠杆菌的抑菌率。实施例1~5所得口腔抑菌组合物对白色念珠菌的抑菌率在5min~2h时均>99.9%,优于各对比例所得的口腔抑菌组合物对白色念珠菌的抑菌率。
试验例2
本试验例考察了上述实施例10~18制备所得口腔抑菌液的急性眼刺激性。
1、实验方法
采用眼部健康的新西兰家兔27只,雌性,体重2.0~2.5kg,以普通级家兔维持饲料喂养,温度20~26℃,相对湿度40%~70%。
根据《消毒技术规范》(2002年版)2.3.4.3对实施例10~18制备所得口腔抑菌液分别进行急性眼刺激试验(各样品以3只家兔进行试验):实验前约24h对家兔两眼进行检查,所选动物均为无眼刺激症状、角膜缺陷及结膜损伤。试验时吸取待测口腔抑菌液0.1ml,滴入家兔一侧眼结膜囊内。另一侧眼以生理盐水作为正常对照。滴受试物后,将眼被动闭合4s,30s后用生理盐水冲洗。于滴眼后分别计算每只动物在1h、24h、48h、72h对眼睛的刺激强度,并根据表6进行急性眼刺激反应评分。结果见表7(表中数值为各样品对应的3只家兔的平均评分)。
表6急性刺激反应评分标准
表7实施例10~18所得口腔抑菌液的试验结果
/>
由表7结果可见,实施例10~18所得口腔抑菌液对白兔眼刺激强度均为无刺激性。
试验例3
本试验例对上述实施例10~14和对比例10~18制备所得口腔抑菌液进行了其对加速口腔溃疡愈合的效果。
1、实验动物
SPF级Wistar大鼠,雌雄各半,体重200g±20g。
2、试验方法
将大鼠随机分为实施例10~14组、对比例10~18组、空白对照组,每组10只。将各组大鼠用乙醚麻醉,仰卧固定,用浸透900g/L苯酚溶液、直径约6mm的棉球在大鼠一侧颊黏膜上灼烧60s,可见颊黏膜上出现直径约5mm左右的白色损害;次日可见大鼠口唇边潮湿,流口水,颊黏膜处红肿,表示造模成功。记录各组大鼠在给药前的溃疡面直径。
将实施例10~14以及对比例10~18组的口腔抑菌液分别浓缩至各自原体积的50%,每天分别对实施例10~14组、对比例10~18组大鼠在溃疡处喷4次,相邻两次之间间隔2h。空白对照组不给药。每次给药后禁食禁水30min,连续给药6d。给药期间内,每天最后一次给药后记录口腔溃疡愈合的总只数,在最后一次给药后12h时记录各组大鼠溃疡面直径,结果如表8所示。
表8各组口腔抑菌液对加速口腔溃疡愈合的试验结果
注:a与空白对照组相比P<0.05;b与实施例10组相比,P<0.05
由表8的结果可见,与空白对照组以及不使用连翘提取液、金银花提取液、甘草提取液和板蓝根提取液的对比例18相比,本发明实施例10~14提供的口腔抑菌液能够显著加速口腔溃疡的愈合,并且与采用其他方式进行连翘、金银花、甘草和板蓝根提取的对比例10~17相比,本发明实施例10~14提供的口腔抑菌液能够更有效地促进使溃疡面直径缩小。
由试验例1、2和3的结果可见,本发明实施例提供的口腔抑菌组合物具有优异的抑菌效果,且对黏膜无刺激。并且,以该口腔抑菌组合物制成的口腔抑菌液能够有效促进口腔溃疡的愈合。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换或改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种口腔抑菌组合物,其特征在于,由以下重量份数的成分组成:连翘提取液0.05~0.3份,金银花提取液0.05~0.3份,甘草提取液0.05~0.3份,板蓝根提取液0.05~0.3份,西吡氯铵0.02~0.1份和葡萄糖酸氯己定0.02~0.1份;
所述甘草提取液的制备方法为:将生甘草粉碎,加入相当于所述生甘草质量5~7倍的水煎煮1~1.5h,降温至40~50℃后,加入相当于所述生甘草质量0.5~1.5%的纤维素酶在40~50℃酶解2~3h,然后升温至90~95℃保持5~10min灭酶,过滤,得酶解液和滤渣;向所述滤渣中加入相当于所述滤渣质量5~7倍的水,在20~30kHz的频率下超声提取20~30min,过滤,得超声提取液;将所述酶解液和所述超声提取液合并后,浓缩至1.2~1.3g/ml,得所述甘草提取液;
所述板蓝根提取液的制备方法为:将板蓝根破碎,加入相当于所述板蓝根质量6~8倍的10~20%v/v乙醇水溶液,在功率为750~950W、温度为30~40℃条件下微波萃取10~15min,过滤,得滤渣和微波提取液;将所述滤渣用15~25%v/v乙醇水溶液回流提取2~3次,每次20~30min,合并回流提取液;将所述微波提取液和所述回流提取液合并,浓缩至1.2~1.3g/ml,得所述板蓝根提取液;
所述连翘提取液的制备方法为:以15~25%v/v乙醇水溶液在25~35℃对连翘进行超声提取,先在25~35kHz的频率下提取20~30min,再在50~70kHz的频率下提取15~25min;提取完成后过滤,将所得滤液浓缩至1.2~1.3g/ml,得所述连翘提取液;其中,所述15~25%v/v乙醇水溶液的质量为所述连翘质量的5~8倍;
所述金银花提取液的制备方法为:以45~65%v/v乙醇水溶液在45~60℃对金银花进行超声提取,先在20~35kHz的频率下超声提取20~30min,再在55~70kHz的频率下超声提取15~20min;提取完成后过滤,将所得滤液浓缩至1.2~1.3g/ml,得所述金银花提取液;其中,所述45~65%v/v乙醇水溶液的质量为所述金银花质量的7~10倍。
2.根据权利要求1所述的口腔抑菌组合物,其特征在于,由以下重量份数的成分组成:连翘提取液0.1~0.2份,金银花提取液0.1~0.2份,甘草提取液0.1~0.2份,板蓝根提取液0.1~0.2份,西吡氯铵0.08~0.1份和葡萄糖酸氯己定0.06~0.08份。
3.根据权利要求2所述的口腔抑菌组合物,其特征在于,由以下重量份数的成分组成:连翘提取液0.1份,金银花提取液0.1份,甘草提取液0.1份,板蓝根提取液0.1份,西吡氯铵0.08份和葡萄糖酸氯己定0.06份。
4.权利要求1~3任一项所述口腔抑菌组合物在制备口腔抑菌产品中的应用。
5.一种口腔抑菌液,其特征在于,包括权利要求1所述的口腔抑菌组合物。
6.根据权利要求5所述的口腔抑菌液,其特征在于,包括以下重量份数的成分:
水75~85份;
保湿剂3~6份;
矫味剂0.05~3.5份;
抗氧剂0.01~0.1份;
乙醇0.1~8份;
聚山梨醇酯-802~8份;
香精0.5~1.2份;
连翘提取液0.05~0.3份;
金银花提取液0.05~0.3份;
甘草提取液0.05~0.3份;
板蓝根提取液0.05~0.3份;
西吡氯铵0.02~0.1份;
葡萄糖氯己定0.02~0.1份。
7.根据权利要求6所述的口腔抑菌液,其特征在于,所述保湿剂为甘油;和/或
所述矫味剂选自木糖醇、三氯蔗糖中的至少一种;和/或
所述抗氧剂为柠檬酸钠。
8.权利要求6或7所述的口腔抑菌液的制备方法,其特征在于,包括以下步骤:
向所述水中加入所述保湿剂、矫味剂、西吡氯铵、葡萄糖酸氯己定和抗氧剂,搅拌至溶解;
加入所述连翘提取液、金银花提取液、甘草提取液和板蓝根提取液,搅拌分散均匀;
加入预混均匀的所述乙醇、聚山梨醇酯-80和香精,混合均匀,得所述口腔抑菌液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010750056.4A CN114053331B (zh) | 2020-07-30 | 2020-07-30 | 一种口腔抑菌组合物、口腔抑菌液、应用及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010750056.4A CN114053331B (zh) | 2020-07-30 | 2020-07-30 | 一种口腔抑菌组合物、口腔抑菌液、应用及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114053331A CN114053331A (zh) | 2022-02-18 |
CN114053331B true CN114053331B (zh) | 2024-02-13 |
Family
ID=80227246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010750056.4A Active CN114053331B (zh) | 2020-07-30 | 2020-07-30 | 一种口腔抑菌组合物、口腔抑菌液、应用及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114053331B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317560A (zh) * | 2022-09-20 | 2022-11-11 | 企点生物科技(上海)有限公司 | 一种大蒜活性抗菌肽口腔喷雾及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101637529A (zh) * | 2008-07-29 | 2010-02-03 | 北京以岭药业有限公司 | 一种中药组合物在制备治疗手足口病药物中的应用 |
CN109481527A (zh) * | 2017-09-11 | 2019-03-19 | 石家庄以岭药业股份有限公司 | 一种制备预防或治疗口腔疾病的中药组合物及其应用 |
-
2020
- 2020-07-30 CN CN202010750056.4A patent/CN114053331B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101637529A (zh) * | 2008-07-29 | 2010-02-03 | 北京以岭药业有限公司 | 一种中药组合物在制备治疗手足口病药物中的应用 |
CN109481527A (zh) * | 2017-09-11 | 2019-03-19 | 石家庄以岭药业股份有限公司 | 一种制备预防或治疗口腔疾病的中药组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114053331A (zh) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104887581B (zh) | 一种口腔护理组合物及其制备方法 | |
CN104666621B (zh) | 一种具有止血、消炎和抑菌作用的中药组合物及含其牙膏 | |
CN105310960B (zh) | 一种新型多糖抗菌漱口液及其制备方法 | |
KR101481371B1 (ko) | 울금을 함유한 치약 조성물 및 그 제조 방법 | |
CN102125513B (zh) | 口腔保健品及其制备方法 | |
CN102198065A (zh) | 一种口腔喷雾剂及其制备方法 | |
CN112336663A (zh) | 一种中药漱口水 | |
CN112263606A (zh) | 一种中药含漱液及其制备方法 | |
CN104435379A (zh) | 一种具有抑菌抗炎、止血和止痛的植物提取物复合物及其应用 | |
CN114053331B (zh) | 一种口腔抑菌组合物、口腔抑菌液、应用及制备方法 | |
WO2016010284A1 (ko) | 울금을 함유한 치약 조성물 및 그 제조 방법 | |
CN110327232B (zh) | 一种救必应漱口水 | |
CN106309746A (zh) | 一种中药组合物及其制备方法和口腔保健品 | |
CN103599182A (zh) | 中药组合物及其制备方法、口腔清洁护理用品及其制备方法 | |
CN109223760B (zh) | 一种苯并呋喃衍生物的用途 | |
CN110731935A (zh) | 一种消炎镇痛牙膏 | |
CN103735481A (zh) | 一种抗菌消炎漱口水及其制备方法 | |
CN108743497A (zh) | 一种植物源抑菌漱口水及其制备方法 | |
CN110638910B (zh) | 一种具有抗病毒抑菌消炎作用的口气清新剂及其制备方法 | |
CN107242983A (zh) | 一种含艾叶黄酮的漱口水及其制备方法 | |
CN108175730B (zh) | 一种用于口腔的组合物及其应用和制备方法 | |
CN111358819A (zh) | 一种具有抗菌止血作用的中药组合物 | |
CN107456395A (zh) | 一种含氧化石墨烯的中药牙膏及其制备方法和应用 | |
CN109646591B (zh) | 一种用于口腔的组合物及其应用 | |
CN107519377B (zh) | 一种抑菌消炎组合物及其制备方法和口腔保健护理产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |